Fundraising FoxDroia Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalEQT Life SciencesEurazeoKurma PartnersPureos Bioventures
VICO is an online platform for finding verified furnished monthly housing — rooms, studios, and apartments — aimed at students, young professionals, and digital nomads relocating to a new city.
B2B MarketplacesConsumerMarketplacesPropTechTravel & HospitalityMedellín, CO
Manuel FranzinTilman Burfeindin
Co-investors500 GlobalEQT Life SciencesEurazeoKurma PartnersPureos Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.